1-4 of 4
Yi Feng
Close
Sort by
Journal Articles

Structural Optimization of Dual-Target CD22/CD19 CAR-T and Its Anti-Tumor Effects on B Cell Malignancies

Yu Zhang, Ying Wang, Runxia Gu, Lin Shi, Yongzeng Wang, Yi Feng, Lulu Lv, Qing Rao, Min Wang, Jianxiang Wang
Journal: Blood
Blood (2022) 140 (Supplement 1): 630–631.
https://doi.org/10.1182/blood-2022-162345
Published: 2022
Journal Articles

Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: A Pivotal Study Report of CNCT19 (inaticabtagene autoleucel) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-Cell ALL) in China

Ying Wang, Xudong Wei, Dongmei Yan, Cheng Zhang, Hongsheng Zhou, Chunrong Tong, Heng Mei, Jie Jin, Ting Niu, Aibin Liang, Jienan Ren, Yiping Deng, Wei Jin, Yi Feng, Lin Shi, Yongzeng Wang, Changting Haudenschild, Lulu Lv, Jianxiang Wang
Journal: Blood
Blood (2022) 140 (Supplement 1): 1598–1600.
https://doi.org/10.1182/blood-2022-165002
Published: 2022
Journal Articles

Numerous ring sideroblasts in chronic neutrophilic leukemia

Yi Feng, Weiying Feng
Journal: Blood
Blood (2021) 138 (18): 1783.
https://doi.org/10.1182/blood.2021013310
Published: 2021
Journal Articles

Early mammalian erythropoiesis requires the Dot1L methyltransferase

Yi Feng, Yanping Yang, Manoela M. Ortega, Jessica N. Copeland, Mingcai Zhang, Jennifer B. Jacob, Timothy A. Fields, Jay L. Vivian, Patrick E. Fields
Journal: Blood
Blood (2010) 116 (22): 4483–4491.
https://doi.org/10.1182/blood-2010-03-276501
Published: 2010
Includes: Supplemental data